Patents by Inventor David C. Griffith

David C. Griffith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetracycline compositions
    Patent number: 9744179
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 29, 2017
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
  • ORITAVANCIN FORMULATIONS
    Publication number: 20170239323
    Abstract: Disclosed herein are antibacterial compositions, pharmaceutical compositions, and the use and preparation thereof. Some embodiments relate to compositions including oritavancin and their use as therapeutic agents.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 24, 2017
    Inventors: David C. Griffith, Adel Rafai Far, Dario Lehoux, Gopal Krishna
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 9717738
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 1, 2017
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • Use of aerosolized levofloxacin for treating cystic fibrosis
    Patent number: 9700564
    Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: July 11, 2017
    Assignee: Horizon Orphan LLC
    Inventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
  • Cyclic boronic acid ester derivatives and therapeutic uses thereof
    Patent number: 9694025
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: July 4, 2017
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • METHODS OF TREATING BACTERIAL INFECTIONS
    Publication number: 20160339045
    Abstract: Methods of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester Compound I in combination with meropenem are disclosed herewith. In some embodiments, the bacterial infection is a lower respiratory tract infection.
    Type: Application
    Filed: April 20, 2016
    Publication date: November 24, 2016
    Inventors: David C. Griffith, Michael N. Dudley, Jeffrey S. Loutit, Olga Lomovskaya
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20160287606
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 6, 2016
    Applicant: Raptor Pharmaceuticals Inc.
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF
    Publication number: 20160279138
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: Raptor Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF
    Publication number: 20160220591
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Application
    Filed: February 3, 2016
    Publication date: August 4, 2016
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 9326936
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: May 3, 2016
    Assignee: Raptor Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • Cyclic boronic acid ester derivatives and therapeutic uses thereof
    Patent number: 9296763
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: March 29, 2016
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • Tetracycline compositions
    Patent number: 9278105
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: March 8, 2016
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Serge Boyer, Michael N. Dudley, Scott Hecker
  • Tetracycline compositions
    Patent number: 9084802
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 21, 2015
    Assignee: REMPEX PHARMACEUTICALS, INC.
    Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
  • TETRACYCLINE COMPOSITIONS
    Publication number: 20150094282
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20140329810
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: David C. GRIFFITH, Michael N. DUDLEY, Mark W. SURBER, Keith A. BOSTIAN, Olga RODNY
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 8815838
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: August 26, 2014
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • TETRACYCLINE COMPOSITIONS
    Publication number: 20140194393
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicant: Rempex Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
  • TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION
    Publication number: 20140105985
    Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: Mpex Pharmaceuticals, Inc.
    Inventors: Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
  • Cyclic boronic acid ester derivatives and therapeutic uses thereof
    Patent number: 8680136
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: March 25, 2014
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF
    Publication number: 20140066441
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 6, 2014
    Applicant: MPEX PHARMACEUTICALS, INC.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny (Lomovskaya), David C. Griffith